Skin Cancers | Clinical

Experts Contemplate Realistic Treatment Goals Using Hedgehog Inhibitors in Basal Cell Carcinoma

March 26, 2021

Hedgehog inhibitors are becoming more widely used for Basal cell carcinoma. Two experts, Shailender Bhatia, MD and Paul T. Nghiem, MD, PhD discussed the reality of hedgehog inhibitor use in practice during a virtual Targeted Oncology Case-Based Roundtable event.

FDA Approves Cemiplimab for Locally Advanced and Metastatic Basal Cell Carcinoma

February 09, 2021

The FDA has approved cemiplimab-rwlc, the PD-1 inhibitor, for the treatment of patients with advanced basal cell carcinoma previously treated with a hedgehog pathway inhibitor or for whom a hedgehog inhibitor is not appropriate.

Rabinowits Analyzes the Use of Anti–PD-1 Therapy in cSCC

February 01, 2021

During a Targeted Oncology Case-Based Peer Perspectives event, Guilherme Rabinowits, MD, medical oncologist/hematologist, Miami Cancer Institute, discussed the case of 69-year-old patients with cutaneous squamous cell carcinoma.